317 related articles for article (PubMed ID: 25485837)
1. BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence.
Gu L; Frommel SC; Oakes CC; Simon R; Grupp K; Gerig CY; Bär D; Robinson MD; Baer C; Weiss M; Gu Z; Schapira M; Kuner R; Sültmann H; Provenzano M; ; Yaspo ML; Brors B; Korbel J; Schlomm T; Sauter G; Eils R; Plass C; Santoro R
Nat Genet; 2015 Jan; 47(1):22-30. PubMed ID: 25485837
[TBL] [Abstract][Full Text] [Related]
2. CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.
Pulukuri SM; Rao JS
Oncogene; 2006 Aug; 25(33):4559-72. PubMed ID: 16786000
[TBL] [Abstract][Full Text] [Related]
3. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation.
Kondo Y; Shen L; Cheng AS; Ahmed S; Boumber Y; Charo C; Yamochi T; Urano T; Furukawa K; Kwabi-Addo B; Gold DL; Sekido Y; Huang TH; Issa JP
Nat Genet; 2008 Jun; 40(6):741-50. PubMed ID: 18488029
[TBL] [Abstract][Full Text] [Related]
4. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
[TBL] [Abstract][Full Text] [Related]
5. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2.
Beke L; Nuytten M; Van Eynde A; Beullens M; Bollen M
Oncogene; 2007 Jul; 26(31):4590-5. PubMed ID: 17237810
[TBL] [Abstract][Full Text] [Related]
6. Methylation of the CD44 metastasis suppressor gene in human prostate cancer.
Lou W; Krill D; Dhir R; Becich MJ; Dong JT; Frierson HF; Isaacs WB; Isaacs JT; Gao AC
Cancer Res; 1999 May; 59(10):2329-31. PubMed ID: 10344738
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines.
Karanikolas BD; Figueiredo ML; Wu L
Prostate; 2010 May; 70(6):675-88. PubMed ID: 20087897
[TBL] [Abstract][Full Text] [Related]
8. BAZ2A-RNA mediated association with TOP2A and KDM1A represses genes implicated in prostate cancer.
Roganowicz M; Bär D; Bersaglieri C; Aprigliano R; Santoro R
Life Sci Alliance; 2023 Jul; 6(7):. PubMed ID: 37184661
[TBL] [Abstract][Full Text] [Related]
9. ATRA inhibits the proliferation of DU145 prostate cancer cells through reducing the methylation level of HOXB13 gene.
Liu Z; Ren G; Shangguan C; Guo L; Dong Z; Li Y; Zhang W; Zhao L; Hou P; Zhang Y; Wang X; Lu J; Huang B
PLoS One; 2012; 7(7):e40943. PubMed ID: 22808286
[TBL] [Abstract][Full Text] [Related]
10. BAZ2A-mediated repression via H3K14ac-marked enhancers promotes prostate cancer stem cells.
Peña-Hernández R; Aprigliano R; Carina Frommel S; Pietrzak K; Steiger S; Roganowicz M; Lerra L; Bizzarro J; Santoro R
EMBO Rep; 2021 Nov; 22(11):e53014. PubMed ID: 34403195
[TBL] [Abstract][Full Text] [Related]
11. Suppression of telomerase, reexpression of KAI1, and abrogation of tumorigenicity by nerve growth factor in prostate cancer cell lines.
Sigala S; Faraoni I; Botticini D; Paez-Pereda M; Missale C; Bonmassar E; Spano P
Clin Cancer Res; 1999 May; 5(5):1211-8. PubMed ID: 10353759
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of IFITM1 has clinicopathologic effects on gastric cancer and is regulated by an epigenetic mechanism.
Lee J; Goh SH; Song N; Hwang JA; Nam S; Choi IJ; Shin A; Kim IH; Ju MH; Jeong JS; Lee YS
Am J Pathol; 2012 Jul; 181(1):43-52. PubMed ID: 22609115
[TBL] [Abstract][Full Text] [Related]
13. Cross-species global and subset gene expression profiling identifies genes involved in prostate cancer response to selenium.
Schlicht M; Matysiak B; Brodzeller T; Wen X; Liu H; Zhou G; Dhir R; Hessner MJ; Tonellato P; Suckow M; Pollard M; Datta MW
BMC Genomics; 2004 Aug; 5(1):58. PubMed ID: 15318950
[TBL] [Abstract][Full Text] [Related]
14. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis.
Darash-Yahana M; Pikarsky E; Abramovitch R; Zeira E; Pal B; Karplus R; Beider K; Avniel S; Kasem S; Galun E; Peled A
FASEB J; 2004 Aug; 18(11):1240-2. PubMed ID: 15180966
[TBL] [Abstract][Full Text] [Related]
15. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
[TBL] [Abstract][Full Text] [Related]
17. The association between histone 3 lysine 27 trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters.
Ngollo M; Lebert A; Dagdemir A; Judes G; Karsli-Ceppioglu S; Daures M; Kemeny JL; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon D
BMC Cancer; 2014 Dec; 14():994. PubMed ID: 25535400
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer.
Kobayashi Y; Absher DM; Gulzar ZG; Young SR; McKenney JK; Peehl DM; Brooks JD; Myers RM; Sherlock G
Genome Res; 2011 Jul; 21(7):1017-27. PubMed ID: 21521786
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of enhancer of zeste homolog 2 (EZH2) characterizes an aggressive subset of prostate cancers and predicts patient prognosis independently from pre- and postoperatively assessed clinicopathological parameters.
Melling N; Thomsen E; Tsourlakis MC; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Wilczak W; Huland H; Simon R; Schlomm T; Steurer S; Krech T
Carcinogenesis; 2015 Nov; 36(11):1333-40. PubMed ID: 26392259
[TBL] [Abstract][Full Text] [Related]
20. DNA methylome analysis identifies epigenetic silencing of FHIT as a determining factor for radiosensitivity in oral cancer: an outcome-predicting and treatment-implicating study.
Lin HY; Hung SK; Lee MS; Chiou WY; Huang TT; Tseng CE; Shih LY; Lin RI; Lin JM; Lai YH; Chang CB; Hsu FC; Chen LC; Tsai SJ; Su YC; Li SC; Lai HC; Hsu WL; Liu DW; Tai CK; Wu SF; Chan MW
Oncotarget; 2015 Jan; 6(2):915-34. PubMed ID: 25460508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
